PMC:7283670 / 36493-36806 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T206","span":{"begin":125,"end":133},"obj":"Disease"},{"id":"T207","span":{"begin":134,"end":143},"obj":"Disease"}],"attributes":[{"id":"A206","pred":"mondo_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A207","pred":"mondo_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"ease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged\nInterpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patien"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T345","span":{"begin":40,"end":44},"obj":"http://purl.obolibrary.org/obo/CLO_0001203"}],"text":"ease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged\nInterpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patien"}

{"project":"LitCovid-sentences","denotations":[{"id":"T329","span":{"begin":6,"end":108},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged\nInterpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patien"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T105","span":{"begin":134,"end":143},"obj":"Phenotype"}],"attributes":[{"id":"A105","pred":"hp_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"ease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged\nInterpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patien"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1121","span":{"begin":89,"end":97},"obj":"Species"},{"id":"1262","span":{"begin":125,"end":143},"obj":"Disease"}],"attributes":[{"id":"A1121","pred":"tao:has_database_id","subj":"1121","obj":"Tax:9606"},{"id":"A1262","pred":"tao:has_database_id","subj":"1262","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged\nInterpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patien"}